IDXX

IDEXX Laboratories, Inc.

HealthcareDiagnostics & ResearchNASDAQ

$574.87

-$2.24 (-0.39%)today

Conviction

0/ 10

Fair Value$750.23

Upside+30.50%

Signal0

Market Cap$44.5B

52W Range$356.14–$769.98

Next EarningsApr 30

Price History

FAIR VALUE ANALYSISMonte Carlo · 5,000 runs · 99% valid

Fair Value$136.13

Current Price$558.32

Upside / Down-75.6%

P(Undervalued)0.0%

P(20%+ Up)0.0%

P(15%+ Down)100.0%

Fair Value Distribution — percentile bands

0.0% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

38.5%/yr

±1.9% · revenue growth to justify current price

FCF-Based Reverse DCF

43.4%/yr

±3.6% · FCF growth to justify current price

THE GAP

Market pricing margin compression or rising capex

KEY VALUE DRIVERS

Spearman correlation — what moves this valuation most

Quick Take

IDEXX Laboratories, Inc.

Trailing P/E42.6x

Forward P/E33.9x

P/S10.3x

EPS (TTM)$13.06

Analyst Target$750.23

Analyst Upside30.5%

No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kMar 2

Conviction: unchanged

IDEXX 2025 10-K: Strong execution, stable growth trajectory, premium diagnostic moat

IDXX delivered 10% organic revenue growth in 2025 with 8.1% CAG Diagnostics recurring revenue growth. Operating margins expanded 90bps on comparable basis to 31.4%. Thesis: recurring diagnostics busin...